A rare look at one patient's brain suggests that clearing amyloid plaques may do more than remove the plaques themselves. Researchers from the Perelman School of Medicine at the University of Pennsylvania, presenting at the 2026 Alzheimer's Association International Conference and publishing in JAMA, examined brain tissue donated by a former clinical trial participant who had received aducanumab.
The man was in his fifties when he was diagnosed with mild cognitive impairment caused by Alzheimer's disease. He received 30 doses of the drug over four and a half years, and died about four years after his last dose. His brain showed an unusual patchwork. The raised ridges of the folded surface, called gyri, had lost most of their amyloid plaques and contained very little tau. The neighboring grooves, called sulci, still held considerable amyloid and carried far more tau tangles, inflammation and tissue degeneration. Scans taken while he was alive had already hinted at this uneven clearance.
The finding matters because researchers have long believed amyloid buildup helps create the conditions in which tau tangles form, but direct human evidence that removing amyloid can limit tau has been scarce, since few people who received amyloid-clearing drugs have had their brains examined after death. Edward B. Lee, MD, PhD, one of the co-senior authors, described the case as a natural comparison of neighboring regions that did and did not clear amyloid, which made it possible to track what followed in each.
The researchers are clear about the limits. The study involved only one person, and it cannot establish how much amyloid must be removed for lasting protection or prove that plaque clearance directly caused the differences in tau and damage. The authors also note that clinical trials usually run about 18 months, while some protective effects may take longer to appear. Open questions include why some brain regions respond better to treatment than others, and whether starting treatment before tau tangles develop could delay or prevent the disease. Ongoing trials are expected to help answer that last question.